Surgical treatment of tricuspid valve insufficiency promotes early reverse remodeling in patients with axial-flow left ventricular assist devices  by Maltais, Simon et al.
Acquired Cardiovascular Disease Maltais et al
A
C
DSurgical treatment of tricuspid valve insufficiency promotes early
reverse remodeling in patients with axial-flow left ventricular assist
devicesSimon Maltais, MD, PhD,a Yan Topilsky, MD,a Vakhtang Tchantchaleishvili, MD,b
Stephen H. McKellar, MD, MSc,a Lucian A. Durham, MD, PhD,a Lyle D. Joyce, MD, PhD,a
Richard C. Daly, MD,a and Soon J. Park, MD, MScaFrom th
Colle
of Mi
Disclosu
Presente
for H
Receive
for pu
Address
Mayo
mayo
0022-52
Copyrig
doi:10.1
1370Objective: The HeartMate II (Thoratec Corp, Pleasanton, Calif) continuous-flow left ventricular assist device
has emerged as the standard of care for patients with advanced heart failure. The objective of this study was to
assess the safety and early effectiveness of concomitant tricuspid valve procedures in patients undergoing
implantation of a HeartMate II device.
Methods: From February 2007 to April 2010, 83 patients underwent HeartMate II left ventricular assist device
implantation. Of these, 37 patients had concomitant tricuspid valve procedures (32 repairs, 5 replacements) for
severe tricuspid regurgitation. The effects of a tricuspid valve procedure on tricuspid regurgitation and right
ventricular remodeling were assessed comparing echocardiographic findings at baseline and 30 days after left
ventricular assist device implantation. Overall survival was also compared.
Results: Patients undergoing a concomitant tricuspid valve procedure had more tricuspid regurgitation (vena
contracta, 5.6  2.1 mm vs 2.9  2.0 mm; P<.001), worse right ventricular dysfunction (right ventricular
end-diastolic area, 33.6  6.2 mm vs 31.6  8.5 mm; P ¼ .05), higher mean right atrial pressure (17.4 
7.1 mm Hg vs 14.9  5.1 mm Hg; P ¼ .03), and a higher Kormos score (2.6  2.1 vs 1.2  1.4; P ¼ .0008)
preoperatively. One month after surgery, tricuspid regurgitation was worse in patients who underwent left ven-
tricular assist device implantation alone (þ18.6%), whereas it improved significantly in patients undergoing
a concomitant tricuspid valve procedure (50.2%) (P ¼ .005). A corresponding significant reduction in right
ventricular end-diastolic area (33.6%  6.2% vs 30.1%  9.7%; P ¼ .03) and a trend toward better right ven-
tricular function (55.5%  79.7% vs 35.7%  60.5%; P ¼ .28) were noted in patients undergoing a concom-
itant tricuspid valve procedure. Survival was comparable between the 2 groups.
Conclusions: In patients with severe tricuspid regurgitation undergoing left ventricular assist device implanta-
tion, a concomitant tricuspid valve procedure effectively reduces tricuspid regurgitation and promotes reverse
remodeling of the right ventricle. (J Thorac Cardiovasc Surg 2012;143:1370-6)Supplemental material is available online.
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Patients with advanced heart failure often present in
biventricular failure, but the primary cause of heart failure
is in the left ventricle in the majority of patients. Clinically,
LVAD implantation alone effectively relieves symptoms in
the majority of patients. However, a variable degree of
residual right ventricular (RV) dysfunction and tricuspid
regurgitation (TR) persists after LVAD implantation.
Topilsky and colleagues4 recently demonstrated the impor-
tance of RV reserve remodeling in determining the long-
term survival after continuous-flow LVAD implantation.
We postulated that concomitant surgical correction of
moderate to severe TR at the time of LVAD implantation
would be important in promoting RV reverse remodeling
and restoring overall survival comparable to those without
significant TR. This study compared 2 groups of patients
undergoing implantation of a HeartMate II (Thoratec
Corp, Pleasanton, Calif) continuous, axial-flow LVAD:
those with and without a concomitant tricuspid valvegery c June 2012
Abbreviations and Acronyms
BTT ¼ bridge to transplantation
DT ¼ destination therapy
LV ¼ left ventricular
LVAD ¼ left ventricular assist device
RV ¼ right ventricular
TR ¼ tricuspid regurgitation
TV ¼ tricuspid valve
TVP ¼ tricuspid valve procedure
VC ¼ vena contracta
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sess the effectiveness of a concomitant TVP on TR volume,
the subsequent RV geometry change, and the overall
survival.
MATERIALS AND METHODS
Study Population
Institutional review board approval from the Mayo Foundation for Ed-
ucation and Research (Mayo Clinic, Rochester, Minn) was obtained with
an exception granted for obtaining study-specific consent. Demographic
and clinical information were obtained from our prospectively collected,
institutional LVAD database. This study included the Mayo Clinic’s con-
secutive experience with the HeartMate II continuous-flow device. All
other device types were excluded from this study. The patients were divided
into 2 groups for comparison based on whether a concomitant TVP was
performed or not at the time of LVAD implantation. We calculated and
compared groups for clinical scores reported by Lietz and colleagues,5
Matthews and colleagues,6 and Kormos and colleagues.7
Surgical Technique
We defined a TVP as either TV repair or replacement (Table 1). The ma-
jority of repairs consisted of placement of a flexible annuloplasty band or
modified Kay annuloplasty stitch with or without De Vega repair.8,9 One
patient had a posterior-septal leaflet reconstruction secondary to implant-
able cardioverter defibrillator lead entrapment combined with a modified
Kay annuloplasty (Figure 1), and one patient had a septal leaflet repair
by placing Gore-Tex neochordae (WL Gore and Associates, Flagstaff,
Ariz). If leaflet pathology existed to the extent that annuloplasty would
not correct TR, the tricuspid valve was replaced with a bioprosthesis.
The Biocor bioprosthetic (St Jude Medical, St Paul, Minn) was used for
all patients requiring concomitant TV replacement in this study.
Echocardiographic Assessment
Echocardiographic examinations were performed in all patients in-
cluded in this study. The results presented in this study reflect early echocar-
diographic analysis. All evaluations were performed within 1 month before
surgery (median, 16 days), and postoperative echocardiographic results
were measured within 30 days (mean, 17 days) after LVAD implantation.
Preoperative hemodynamic catheterizations were also obtained. Two-
dimensional transthoracic echocardiography was performed using the
Sonos 5500 (Phillips Medical Systems, Andover, Mass), Sequoia 512
(Siemens Medical Solutions USA, Inc, Mountain View, Calif), or Vivid 7
(GE Medical Systems, Milwaukee, Wis) as described.10-12 Right atrial
pressure was estimated by the inferior vena cava diameter and its
response to inspiration.13 RV function, TR, andmitral regurgitation severity
were quantitatively graded using a 4-point scale (severe¼ 4, moderate¼ 3,The Journal of Thoracic and Carmild¼ 2, and trivial or normal¼ 1). The severity of TR was assessed using
color flow imaging and vena contracta (VC) width.14 RV function was fur-
ther described using tissue Doppler assessment of lateral tricuspid annular
motion15 and the RV index of myocardial performance.16
Definition of Terms
The operative mortality was defined as death from any cause within 30
days of LVAD implantation or during the same hospitalization. RV failure
was defined as the need for inotropic support for more than 14 days post-
operatively or implantation of an RV assist device.
Statistical Analysis
Descriptive statistics for categoric variables are reported as frequency
and percentage, and continuous variables are reported as mean (standard
deviation) or median (range) as appropriate. In this study, patients with
a concomitant TVP were compared with patients undergoing LVAD
implantation alone. Variables were compared using the chi-square or
Kruskal–Wallis tests when appropriate, and continuous variables were
compared using a 2-sample t test orWilcoxon rank-sum test. All 83 patients
were included in the analysis.
For each end point, Kaplan–Meier method was used to draw freedom-
from-event curves and calculate freedom-from-event statistics. The soft-
ware used for analysis was JMP version 8.0 (SAS Institute Inc, Cary, NC).
RESULTS
Patients
Between February 2007 and June 2010, we identified 83
consecutive patients who had a HeartMate II continuous-
flow LVAD (Thoratec Corporation, Pleasanton, Calif) im-
planted for DT or BTT. Thirty-four patients underwent
a concomitant TVP, and the remaining 49 patients under-
went LVAD implantation alone. The echocardiographic
studies were completed in 100% of patients, and preopera-
tive right heart hemodynamic studies were completed in 80
patients (96.4%).
Preoperative Baseline Characteristics
The preoperative baseline characteristics of patients are
shown in Table 2. Results are expressed for the entire pa-
tient population (n ¼ 83) and compared for patients with
and without a TVP. The mean age was 62.9  12.0 years,
and 81.3% were men. Patients undergoing concomitant tri-
cuspid interventions were more likely to be in New York
Heart Association functional class IV (71% vs 55%;
P ¼ .02), to require a preoperative intraaortic balloon
pump (44% vs 27%; P¼ .03), or to have had prior sternot-
omy (56% vs 47%; P ¼ .006) than patients without a TVP.
All other clinical, hemodynamic, and laboratory character-
istics were comparable between groups (P>.05). Preoper-
ative clinical scores revealed comparable risks between the
2 groups. However, Kormos score indicated a significantly
higher risk of RV failure postimplantation for patients un-
dergoing a TVP (2.6  2.1 vs 1.2  1.4; P ¼ .0008).
Surgical Data and Tricuspid Valve Procedure
The details of TV replacement or repairs are summarized
in Table 1. The majority of TVPs were repairs. Simplediovascular Surgery c Volume 143, Number 6 1371
TABLE 1. Tricuspid valve procedures
Tricuspid valve procedures (n ¼ 34) n
Repairs (28)
Kay annuloplasty alone 15
De Vega annuloplasty alone 1
KayþDe Vega annuloplasty 6
Partial ring annuloplasty
Annuloflex (Carbomedics, Austin, Tex) 34 mm 1
Annuloflex (Carbomedics) 36 mm 3
Other
Gore-Tex (WL Gore and Associates,
Flagstaff, Ariz) neochordae (septal leaflet)þKay
1
Reconstruction septal leafletþKay 1
Replacements (6)
Biocor (St Jude Medical, St Paul, Minn) 29/31/33 mm 1/1/4
FIGURE 1. Concomitant TV repair during implantation of a HeartMate II
device (Thoratec Corp, Pleasanton, Calif) using a modified Kay stitch. A,
Severe TR resulted from scattered adhesions between the implantable car-
dioverter defibrillator lead and the septal leaflet of the TV. B, The valve
leaflet was carefully cut to free the implantable cardioverter defibrillator
lead. The remaining edges were reapproximated using 5-0 Prolene sutures.
The implantable cardioverter defibrillator lead was placed at the commis-
sure between the septal and posterior leaflets. A 4-0 Prolene suture was
placed to plicate the tricuspid annulus at the posteroseptal commissure to
reduce the effective annulus of the TV (modified Kay stitch).
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sure between septal and posterior leaflets with pledgeted
4-0 Prolene were effective in reducing TR. In some patients
with more pronounced TVannular dilatations, the De Vega
or flexible annuloplasty bands were added. Amore complex
TV leaflet repair or placement of Gore-Tex neochordae was
performed in a minority of patients. The additional time
required for a TVP was approximately 20 minutes on car-
diopulmonary bypass support. In this study, all surgeries
were performed without aortic crossclamping.
Preoperative Echocardiographic Data
Table 3 shows preoperative echocardiographic and LVAD
parameters. For most parameters estimating left ventricular
(LV) systolic function and filling pressures, there were no
significant differences between the 2 groups. Preoperative
LV end-systolic diameter was smaller for patients in the
TVP group (57.7  10.6 mm vs 63.6  7.6 mm; P ¼ .01).
When considering RV parameters, therewere significant dif-
ferences between groups. The RV end-diastolic and end-
systolic areas were both significantly higher for the TVP
group (33.6  6.2 mm vs 30.1  9.7 mm, P ¼ .05; and
25.3  5.6 mm vs 21.6  8.0 mm, P ¼ .02). The observed
preoperative right atrial pressure was higher for patients in
the TVP group (17.4  7.1 mm Hg vs 14.0  6.1 mm Hg;
P ¼ .03). As expected, TR and TR VC were more pro-
nounced in the TVP group (3.7  1.9 mm vs 1.6  1.5
mm,P<.001; and 5.6 2.1 mm vs 2.9 2.0mm,P<.001).
Postimplant Echocardiographic Data Assessment
After LVAD implantation, therewere significant echocar-
diographic differences between the 2 groups (Table E1). As
expected, patients in the TVP group had a significant reduc-
tion in TR grade and TRVC (TRVC change,50.2%). TR
VC actually worsened in patients without a TVP after
LVAD implantation (TRVC change,þ18.6%). A favorable
effect of TR surgery on RV geometry was documented in1372 The Journal of Thoracic and Cardiovascular Surthe TVP group. The RV end-diastolic area and end-
systolic area change (reduction) were more pronounced
compared with patients with no TR intervention (33.6%
 6.2% vs 30.1%  9.7%, P ¼ .03; and 23.4% 
20.0% vs9.0%  28.2%, P ¼ .02). Although there was
a trend toward a more pronounced RV function recovery
in patients with a concomitant TVP, RV fractional area con-
traction and right index of myocardial performance change
did not reach statistical significance (þ55.5%  79.7% vs
þ35.7%  60.5%, P ¼ .28; and þ23.0%  52.4% vs
þ38.6%  41.7%, P ¼ .30).
Clinical Outcomes
Postoperative complications are outlined in Table 4. Al-
though patients were sicker in the TVP group beforegery c June 2012
TABLE 2. Baseline characteristics and operative details of all patients stratified by tricuspid valve procedure
All patients
n ¼ 83
TVP
n ¼ 34
No TVP
n ¼ 49 P value
Age (y) 62.9  12.0 64.0  12.0 61.6  12.7 .38
Men/women (%) 81.3/18.1 70.6/29.4 89.8/10.2 .03*
NYHA functional class
IIIb 40 29 45 .02*
IV 60 71 55
Prior sternotomy (%) 51 56 47 .006*
Preoperative IABP (%) 31 44 27 .03*
Preoperative inotropic use (%) 74 78 72 .55
DT (%) 67 71 61 .60
Type of cardiomyopathy
Ischemic heart disease 54 50 52 .84
Dilated cardiomyopathy 34 41 33
Restrictive heart disease 10 6 12
Other 2 3 3
Mean heart rate (beats/min) 77.1  14.0 76.1  16.2 78.0  13.9 .58
Mean systolic blood pressure (mm Hg) 99.4  14.0 99.3  13.7 99.5  15.2 .95
Mean diastolic blood pressure (mm Hg) 62.4  10.0 62.2  11.7 66.0  9.3 .15
Hemoglobin (g/dL) 11.8  2.0 11.4  1.9 12.2  1.8 .06
PVR (Woods units) 4.2  3.0 4.4  3.0 3.5  3.0 .20
Bilirubin (mg/dL) 1.2  0.7 1.3  0.8 1.2  0.7 .57
BUN (mg/dL) 31.0  16.0 33.2  18.5 29.5  15.1 .87
Creatinine (mg/dL) 1.3  0.5 1.3  0.4 1.3  0.5 .94
NT-BNP (pg/mL) 5.7  5.2 6.5  6.6 5.6  5.2 .60
Albumin 3.7  0.8 3.7  0.6 3.8  0.5 .35
INR 1.4  0.4 1.4  0.4 1.4  0.4 .95
Leitz-Miller score 9.7  5.7 9.8  5.9 9.6  5.7 .59
Matthews score 1.34  1.9 1.9  3.0 0.9  1.8 .09
Kormos score 1.9  1.9 2.6  2.1 1.2  1.4 .0008*
NYHA,New York Heart Association;DT, destination therapy; IABP, intraaortic balloon pump; PVR, pulmonary vascular resistance; BUN, blood urea nitrogen; INR, international
normalized ratio; NT-BNP, N-terminal brain natriuretic peptide. *Statistically significant difference between TVP vs no TVP groups.
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comparable between the 2 groups. The early incidence of
RV failure and the need for a postoperative RV mechanical
support were comparable between the no TVP and TVP
groups (26% vs 36%, P ¼ .51; 4% vs 6%, P ¼ .69). A
trend toward increased operative mortality was noted in
the TVP group (16.6% vs 4.1%, P ¼ .07), but the overall
survivals were comparable (Figure 2).
DISCUSSION
Widely approved as BTT or DT, the HeartMate II device
is used with increased frequency because it is easy to im-
plant and has been associated with a significant improve-
ment in survival and durability.1-3 Few series have studied
the surgical results of a concomitant TVP or the early
effect of a continuous-flow LVAD on RV remodeling and
TR.10,17,18 Short-term results fromMaeder and colleagues17
have reported a trend toward beneficial RV remodeling
demonstrated by a reduction in the tricuspid annulus plane
systolic excursion. However, they failed to demonstrate
a significant improvement in RV fractional area shorteningThe Journal of Thoracic and Car4 months after LVAD implantation. Lee and colleagues18
recently proposed an early (3–6 months) favorable effect
of the HeartMate II device in the improvement of RV
function.
Nevertheless, severe TR and significant RV dysfunction
have consistently been identified as preoperative predictors
of poor RV function and high mortality after LVAD implan-
tation.19-21 In contrast with the LV, RV function recovery
is fully dependent on the degree of LV unloading and
associated decrease in pulmonary artery pressures. In
addition, RV failure post-LVAD implantation can be precip-
itated by multiple causes, including the acute development
of postoperative pulmonary artery hypertension, alterations
in mechanical relationship between the RV and the ‘‘un-
loaded’’ LV, or further impairment of RV contractility after
inadequate myocardial preservation during surgery or
superimposed nonrevascularized territory.18 On the other
hand, Frazier and colleagues22 have raised significant
concerns regarding RV function and axial-flow devices, pro-
posing that the nonphysiologic leftward shift of the interven-
tricular septum could lead to progressive RV dysfunction.diovascular Surgery c Volume 143, Number 6 1373
TABLE 3. Echocardiographic, catheterization, and left ventricular assist device parameters
All TVP No TVP P value
LV parameters
LV diastolic diameter (mm) 67.2  9.0 65.4  10.1 68.5  9.0 .15
LV systolic diameter (mm) 60.8  9.0 57.7  10.6 63.6  7.6 .01*
Ejection fraction (%) 19.7  7.0 18.3  6.0 20.9  10.2 .18
LV diastolic parameters
Left atrial volume (mL) 133.0  39.0 127.4  35.7 137.7  57.7 .40
E-wave velocity (m/sec) 1.0  0.4 1.1  0.5 1.0  0.3 .26
E-wave deceleration time (msec) 135.9  30.0 133.4  35.4 137.3  27.7 .65
E/e’ ratio 27.5  12.0 27.1  10.3 27.8  12.8 .79
RV parameters
RV end-diastolic area (cm2) 31.6  8.5 33.6  6.2 30.1  9.7 .05*
RV end-systolic area (cm2) 23.2  7.3 25.3  5.6 21.6  8.0 .02*
RV fractional area (%) 0.3  0.1 0.3  0.1 0.29  0.1 .08
RV ejection time corrected (s) 302.8  38.8 305.6  45.7 300.4  31.9 .60
Tricuspid annulus end-systolic diameter (cm) 3.7  0.7 3.71  0.5 3.7  0.6 .72
TV ejection time (ms) 466.9  69.1 449.6  76.5 481.7  59.1 .04*
Estimated RA pressure (mm Hg) 14.9  5.1 17.4  7.1 14.0  6.1 .03*
Mean pulmonary pressure (mm Hg) 36.1  9.3 36.2  8.6 36.0  9.9 .90
Wedge pressure (mm Hg) 23.4  7.3 23.7  6.7 23.4  7.1 .85
RA/wedge ratio 0.7  0.3 0.8  0.3 0.6  0.3 .11
Preoperative RIMP 0.6  0.2 0.5  0.2 0.6  0.2 .09
TV lateral annulus velocity (m/sec) 0.1  0.1 0.1  0.1 0.09  0.03 .71
RV functional grade>moderate (%) 50 30 32 .10
LVAD parameters
Pump speed (rpm) 9425  250 9462  320 9504  254 .58
Pump flow discharge (L/min) 5.2  0.7 5.2  0.6 5.2  0.7 .63
LVAD inflow pulsatility index 5.0  0.7 4.9  0.7 5.0  0.7 .54
RA, Right atrial; RIMP, right index of myocardial performance. *Statistically significant difference between TVP vs no TVP groups.
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quences of continuous-flow mechanical circulatory support
on TR and to assess the effectiveness of a TVP in patients
with moderate to severe TR. The present study has several
unique features compared with previously published stud-
ies: (1) The series comprises a large surgical population
with or without a TVP in a contemporary population with
an axial-flow LVAD; (2) the surgical procedure is closely
associated to echocardiographic data and focuses on several
right-sided parameters known to be important in early RV
function and recovery, TR severity, and RV remodeling;
and (3) early survival and surgical outcomes are compared
between patients with or without a TVP.
Effect of Simple Concomitant Tricuspid
Regurgitation Procedure
Asothergroups have proposed,22,23 our studydemonstrated
a possible early unfavorable effect of continuous-flow
physiology on mild to moderate TR because an early sig-
nificant increase in TR VC was observed in patients in
the no TVP group (þ18.6%). In patients in the TVP
group who survived implantation, we confirmed the early
effectiveness of a TVP by demonstrating a significant re-
duction in TR VC (TR VC change, 50.2%; P ¼ .0051374 The Journal of Thoracic and Cardiovascular Surcompared with the no TVP group). Compared with pa-
tients with no TVP, patients in the TVP group demon-
strated RV geometry changes that were consistent with
reverse remodeling and improved RV function. Although
patients in the TVP group represented a sicker patient
population with more RV dysfunction at baseline, the
overall survival and incidence of postoperative complica-
tions and RV failure requiring RV assist device implanta-
tion or prolonged inotropic support were comparable
between the 2 groups. Simple and effective surgical cor-
rective strategies, such as the Kay, De Vega, or partial
band annuloplasty, resulted in significant improvement
of TR. Although more challenging, these concomitant
repairs were all performed with a minimal increase in
cardiopulmonary bypass time (115.8  30.9 minutes vs
94.4  33.6 minutes; P ¼ .006). This finding is in con-
tradiction with recently published results by Saeed and
colleagues,24 who showed without echocardiographic
data that a concomitant TVP in patients with severe TR
significantly prolonged operative time and did not change
outcomes. However, recent reports suggest that significant
TR is an important marker for RV dilatation and dysfunc-
tion; its presence before LVAD implantation signals
a greater risk of RV failure after LVAD implantationgery c June 2012
TABLE 4. In-hospital or 30-day complications after left ventricular assist device implantation in patients with or without a tricuspid valve
procedure
All TVP No TVP P value
Cardiopulmonary bypass time (min) 103.3  34.0 115.8  30.9 94.4  33.6 .006*
Infection (%) 49 36 57 .06
Acute cerebral event (%) 12 15 8 .32
Prolonged intubation (%) 23 27 20 .47
Acute renal failure (%) 16 15 16 .87
Dialysis (%) 10 18 7 .16
Hepatic dysfunction (%) 18 21 16 .58
Arrhythmias (%) 20 15 22 .41
Early hemolysis (%) 2 1 3 .51
Pump flow (L/min) 5.1  0.7 5.6  0.9 5.3  0.8 .28
RV failure>moderate (%) 24 26 36 .51
Mean RA pressure (mm Hg) 12.8  5.4 14.7  5.3 11.5  5.1 .02*
Mean PAP (mm Hg) 26.8  7.2 28.8  9.0 25.3  5.0 .09
Need RVAD (%) 4 6 4 .69
Duration inotropic support (h) 197  274 207  286 191  270 .80
Prolonged inotropic support (%) 13 15 12 .75
30-d mortality (%) 9.6 17.6 4.1 .07
Hospital LOS (d) 21  14 23  16 20  12 .46
LOS, Length of stay; PAP, pulmonary artery pressure; RA, right atrial; RVAD, right ventricular assist device. *Statistically significant difference between TVP vs no TVP groups.
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wise, Dreyfus and colleagues26 clearly showed that tri-
cuspid repair is beneficial not only in reducing TR but
also in decreasing RV volume, which may help improve
overall RV performance.26
In view of our experience of a concomitant TVP at the
time of LVAD implantation, we recommend an aggressive
surgical approach to address moderate to severe TR in
patients undergoing implantation of an axial-flow LVAD.
According to our surgical results, a concomitant TVP isFIGURE 2. Kaplan–Meier estimate of survival in patients with or without
a TVP. Kaplan–Meier estimate comparing patients with or without
a concomitant TVP at the time of the HeartMate II device implantation.
TR, Tricuspid regurgitation.
The Journal of Thoracic and Careffective in reducing TR and positively altering RV geome-
try. This observation of a TVP possibly having a positive
impact on RV function may be of significant importance.
In patients awaiting heart transplantation, a TVP could be
beneficial to optimize RV reverse remodeling and facilitate
patient management; whereas in patients with DT implanta-
tions, a concomitant TVP could be performed to optimize
functional and survival outcomes.Limitations
This study was retrospective and not randomized. All pa-
tients with moderate to severe TR over the study period
were aggressively treated with repair or replacement.
Thus, conclusions on the impact of LVAD implantation
alone on significant TR are hard to draw. There are several
controversies regarding the impact of LVAD implantation
alone on moderate to severe TR. A National Institutes of
Health-sponsored randomized trial may help determine
whether a TVP would have a positive impact on clinical
outcomes and survival. However, in most cases, a relatively
simple procedure can be performed quickly, without cardi-
oplegic arrest. In this study, a concomitant TVP not only
reduced TR but also improved RV remodeling. Another
limitation of this study is that echocardiographic follow-
ups were not performed as part of a protocol, but rather
were obtained when clinically indicated. Finally, other
echocardiographic parameters, such as the degree of eccen-
tricity of the TR immediately pre- and postbypass, were not
evaluated. Such measures could be used to assess the initial
response of the tricuspid valve to LVAD implantation and
guide the surgeon’s decision to address residual TR.diovascular Surgery c Volume 143, Number 6 1375
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In patients with mild to moderate TR, the early changes
associated with an axial-flow physiology worsen the degree
of TR in patients with no TVP. At the time of LVAD implan-
tation, performing a concomitant TVP using simple repair
techniques or a TV replacement in patients with more
advanced RV dysfunction leads to improvement in TR,
early RV remodeling, and possibly RV function. Despite
a higher preoperative calculated risk of RV failure in pa-
tients undergoing a TVP, postoperative complications and
early survival were comparable between groups. We there-
fore propose an aggressive TR surgical reducing strategy
in patients with more than moderate TR at the time of
HeartMate II LVAD implantation. Promoting early RV re-
verse remodeling is important, especially in the era of DT.
Given the exploratory nature of the results, validation in
larger patient cohorts is still required.
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TABLE E1. Echocardiographic changes after left ventricular assist device implantation in patients with or without a tricuspid valve procedure
TVP No TVP P value
TR>moderate (%) 12 24 .42
Postoperative TR VC 2.5  1.7 2.6  1.9 .89
TR VC change (%) 50.2  38.1 þ18.6  120.9 .005*
RVFAC change (%) þ55.5  79.7 þ35.7  60.5 .28
RIMP change (%) 23.0  52.4 38.6  41.7 .30
RVEDA change (%) 33.6  6.2 30.1  9.7 .03*
RVESA change (%) 23.4  20.0 9.0  28.2 .02*
RIMP, Right index of myocardial performance; RVEDA, right ventricular end-diastolic area; RVESA, right ventricular end-systolic area; RVFAC, right ventricular fractional area
contraction. *Statistically significant difference between TVP vs no TVP groups.
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